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Background: Primary biliary cirrhosis (PBC) is a liver specific chronic disease with unclear pathogenesis, especially
for the early stage molecular events. The mitochondrion is a multi-functional organelle associated with various
diseases including PBC. The purpose of this study was to discover the alterations in the mitochondria proteome
using an early stage PBC mouse model for revealing the possible pathogenesis mechanisms in the early stages of
PBC.
Methods: Mouse model of early stage of PBC was constructed by consecutive administration of poly I:C.
Mitochondria of mouse models and controls were purified and comparative proteomics was performed by iTRAQ
technology. Then, differentially expressed proteins were validated by western blotting.
Results: In total 354 proteins that satisfied the criteria for comparative proteomics study were identified. Of them,
nine proteins were downregulated and 20 were up-regulated in liver mitochondria of PBC mouse model. Most
differentially expressed proteins are associated with oxidation-reduction and lipid metabolism, and some are
involved in the biosynthesis of steroid hormone and primary bile acid. Interestingly, four proteins (HCDH, CPT I,
DECR, ECHDC2) involved in the fatty acid beta-oxidation were all upregulated.
Conclusions: iTRAQ is a powerful tool for comparative proteomics study of PBC mouse model and differentially
expressed proteins in mitochondria proteome of PBC mouse model provide insights for the pathogenesis
mechanism at early stage of PBC.
Keywords: Primary biliary cirrhosis, Proteomics, iTRAQ, Molecular pathogenesisBackground
Primary biliary cirrhosis (PBC) is a chronic inflamma-
tory liver disease characterized by progressive destruc-
tion of small and medium-sized bile ducts, which
leads to cholestasis, liver fibrosis, cirrhosis, and ultim-
ate liver failure [1,2]. It primarily affects middle-aged
women, with the ratio of female/male patients at about
8–10:1 [3,4]. PBC is considered as an autoimmune* Correspondence: wul@big.ac.cn; yongzhelipumch@yahoo.com.cn
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reproduction in any medium, provided the ordisease and the serologic hallmark is high titers of anti-
mitochondria antibodies (AMA), whose main target is
the lipoyl domain of the E2 subunits of the 2-oxo-acid
dehydrogenase complexes located at mitochondrial
inner membrane.
PBC progresses through four histological stages
according to the guidelines approved by the American
Association for the Study of Liver Diseases (AASLD).
Stage I is characterized by portal inflammation with or
without florid bile duct lesions and the inflammation is
restricted to portal area. At stage II, periportal lesions
extend into the hepatic parenchyma. Stage III is charac-
terized by a distortion of the hepatic architecture with
numerous fibrous septa. Cirrhosis with the existence of
regenerative nodules defines stage IV [5].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tiple genetic and environmental factors, but the molecu-
lar pathogenesis is still enigmatic, especially for cellular
process at early stages, which might be important for
discovery of the Pandora box of PBC. Through the litera-
ture search, we found mitochondria might be involved in
the pathogenesis of PBC. First, in vitro treatment of poly
I:C, a synthetic analog of viral double-stranded RNA
(dsRNA), induced mitochondrial dysfunction in cultured
human hepatocytes [6]. Second, in the condition of chole-
stasis, the retention of hydrophobic bile acids can induce
oxidative damage, causing mitochondrial dysfunction, and
induce endoplasmic reticulum stress, which were involved
in triggering apoptosis of hepatocyte and biliary epithe-
lial cells [7]. Furthermore, mitochondria had been con-
firmed to be involved in the processing of liver fibrosis
in diseases of viral hepatitis [8], alcoholic and nonalcoholic
steatohepatitis [9], drug-induced liver injury [10], and so
on. A close look at proteome level alterations in liver
mitochondrial proteins might reveal some insights for
PBC pathogenesis.
However, it is difficult to carry out the molecular re-
search at early stage of PBC, as for most patients present
with clinical symtoms in the later stages. Mouse models
have been served as powerful tools in the pathogenesis
research of various diseases. Okada et al. reported that
consecutive administration of Poly I:C to C57BL/C in-
duced PBC like lesions and serological AMA similar to
features of PBC [11], and was considered as mouse
model for research at the early stage of PBC [12-14].
As an initial step to reveal the pathogenesis development
of PBC, in this study, we prepared PBC mouse model by
consecutive injection of poly I:C to C57BL/6 mice and
quantitatively compared liver mitochondria proteome be-
tween model and control groups by iTRAQ technique.
Gene ontology analysis was performed to classify the differ-
entially expressed proteins. At last, some differentially




Mouse model was constructed according to the method
described previously [11,13] with minor modification.
Adult 6–8 week-old C57BL/6 female mice were
injected intraperitoneally twice a week with poly I:C
(Sigma-Aldrich, St. Louis, USA) (PBC model group) at
a dose of 5 mg/kg body weight or with the same volume
of saline water (control group). Mice were sacrificed by
cervical dislocation at three time points: four, eight, and
12 weeks after initiation of injection. Livers were col-
lected and washed three times with saline water. Each
liver was cut into two pieces. The small piece was im-
mediately fixed in buffered formalin for pathologicalstaining, and the large piece was subjected to mitochondria
purification. All mice were maintained in a pathogen-free
facility at Institute of Basic Medical Sciences Chinese
Academy of Medical Sciences (Beijing, China) and received
humane care before sacrifice.
Histopathological analysis
Liver samples were fixed in formalin solution and then
embedded in paraffin. Subsequently, the embedded liver
tissue was cut into thin slices. After deparaffinization,
liver slices on the slides were stained with hematoxylin
and eosin (H&E). The Infiltration of Inflammatory cells
in the liver tissues was evaluated with light microscopy
by senior pathologist at Beijing Union Medical College
Hospital [5].
Purification of mitochondria
Mitochondria purification was conducted following
the method described previously [15]. In short, liver
samples were minced and homogenized in pre-cooled
homogenization buffer (0.25 M sucrose, 10 mM
HEPES pH 7.5, 1 mM EDTA, 0.5 mM EGTA, 1 mM
PMSF, 1 mM NaF and 0.2 mM Na3VO4). Crude mito-
chondria were enriched by differential centrifugation,
and were further purified by centrifugation in a 20-34%
Nycodenz density gradient at 52,000 g for 90 min.
Mitochondria fraction was collected at the interface of
25/30% density and resuspended in mitochondrial
resuspending buffer (200 mM mannitol, 50 mM su-
crose, 10 mM Tris–HCl, pH 7.4, 1 mM EDTA, 0.5 mM
EGTA, 1 mM PMSF, 1 mM NaF and 0.2 mM Na3VO4).
An additional centrifugation at 20,000 g for 30 min was
carried out to get the final purified mitochondria pellet.
The pellets were stored at-80°C until use. The purity of
the mitochondria were evaluated by western blotting
using mitochondria specific antibody, anti-ATPase
subunit beta (ATPB) antibody (Santa Cruz, CA, USA),
and cytoplasm specific antibody, anti-ALD antibody
(Beijing protein innovation Ltd., Co., Beijing, China).
Mitochondria protein preparation and trypsin digestion
Total mitochondria proteins were prepared by dissolving
the purified mitochondria pellet into lysis buffer (7 M
urea, 2 M thiourea, 4% CHAPS, 1 mM PMSF, 2 mM
EDTA and 40 mM Tris–HCl). After sonication and cen-
trifugation at 20,000 g for 10 min, the supernatant were
collected as mitochondrial proteome solution. Protein
concentration was measured using Bradford method.
Equal amount of mitochondria protein from four mice
of the same group at 12-week time point were pooled for
further analysis. After reduction and alkylation, pooled
mitochondrial proteins were precipitated by pre-cooled
acetone and resolved by 50% Tetraethylammonium
Bromide (TEAB) (Sigma-Aldrich, St. Louis, USA), and
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by sequence grade trypsin (Promega, Madison, WI) for
36 h at 37°C before stopped by 0.1% formic acid (FA). At
last, the digested samples were dried in a centrifugal vac-
uum concentrator.
Peptide labeling and separation
Peptide pellets from mitochondrial protein of model and
control groups were individually dissolved in 30ul of 50%
TEAB with 70 μL isopropanol, and then labeled with
iTRAQ reagents 113, and 115, respectively, according to
the manual of 8-plex iTRAQ labeling kit (Applied
Biosystems, Foster City, CA, USA). The labeling effi-
ciency for each sample was 98.0%. The labeled peptides
from two groups were mixed together and unbound
iTRAQ reagents were removed through Strata™-X-C
(Phenomenex Inc., Torrance, CA, USA). Subsequently,
the labeled peptides were separated based on their iso-
electric points (pI) by isoelectric focusing (IEF) on a
Multiphor II unit (GE Healthcare, Fairfield, CT, USA)
using an Immobiline Drystrip Gradient (IPG) pH 3–10
gel (GE Healthcare, Fairfield, CT, USA). Then, the strips
were cut into 44 equal pieces along pH gradient, and
each piece was consecutively incubated in 100ul of 0.1%
FA, 0.1%FA/50% Acetonitrile (ACN), and 0.1%FA/80%
ACN for 10 min each to extract labeled peptides from
gel. The extractions from the same gel piece were com-
bined as one fraction and dried in a centrifugal vacuum
concentrator. Each fraction was desalted using Strata™-X
column (Phenomenex Inc., Torrance, CA, USA) according
to its manual. The samples were then dried using a vac-
uum centrifuge followed by resuspension in 30ul 0.1%
(v/v) formic acid. The relative amount of peptides in
each fraction was estimated by sampling with MALDI-
TOF (Bruker Daltonics Inc, Waltham, USA), and some
adjacent fractions with lower signals were pooled and
dried using a vacuum centrifuge and then re-dissolved
in 20ul 0.1% (v/v) formic acid.
ESI-Q-TOF analysis
Analysis of peptides was processed by Quadrupole-Time
of Flight Mass spectrometer, MicroTOF-Q II (Bruker
Daltonics Inc, Waltham, USA), after reverse phase liquid
chromatography. Firstly, 10ul of peptides in each frac-
tion were subjected to liquid chromatography (Proxeon
Easy nano-LC, Odense, Denmark) on a C18 reverse
phase column (100 mm × 75um) for 120 min at a flow
of 0.3ul/min of a mixture of two solvents. Solvent A was
water/0.1% formic acid, and solvent B was ACN/0.1%
formic acid. The percentage of solvent B to the total
flow was changed to 5%, 45%, 80% and 5% at 0 min,
10 min, 80 min, and 100 min point, respectively. Mass
spectra were performed in a data dependent mode in
which three most abundant ions for each MS scan wereselected for MS/MS analysis within 50-3000 m/z scan
range. Trypsin autolysis products and keratin-derived
precursor ions were automatically excluded. Raw data
files were converted into Mascot Generic Format (MGF)
files with Data Analysis Software (Bruker Daltonics Inc,
Waltham, USA) and then merged into a single MGF file
for all fractions.
Database searching
MS/MS data searching was processed with Mascot soft-
ware (Matrix Science, London, UK; version Mascot).
Mascot was set up to search the ipi.MOUSEv3.79 database
assuming the digestion enzyme trypsin, and then searched
with a fragment ion mass tolerance of 0.05 Da and a parent
ion tolerance of 0.05 Da. Iodoacetamide derivative of
cysteine was specified in Mascot as a fixed modification.
S-carbamoylmethylcysteine cyclization (N-terminus) of
the n-terminus, oxidation of methionine and iTRAQ-
8plex of lysine, tyrosine and the n-terminus were speci-
fied in Mascot as variable modifications.
Protein identification and quantitative analysis
In order to make the quantification more accurate,
Scaffold (version Scaffold_3.3.1, Proteome Software Inc.,
Portland, OR) was used to validate MS/MS based peptide
and protein identifications resulted from Mascot search.
Peptide identifications were accepted if they could be
established at greater than 95.0% probability as speci-
fied by the Peptide Prophet algorithm [16] (Keller, A
2002). Protein identifications were accepted if they
could be established at greater than 99.0% probability
and contained at least 2 identified unipeptides. Protein
probabilities were assigned by the Protein Prophet al-
gorithm [17]. Proteins that contained similar peptides
and could not be differentiated based on MS/MS ana-
lysis alone were grouped to satisfy the principles of par-
simony. In this study, the false discover rates (FDR) of
protein identification at both peptide and protein levels
were 0.0%.
Peptides met the above criteria were quantified using
the centroided reporter ion peak intensity. Intra-sample
channels were normalized based on the median ratio for
each channel across all proteins. Multiple isobaric tag
samples were normalized by comparing the median pro-
tein ratios for the reference channel. Protein quantitative
values were derived only from uniquely assigned pep-
tides. The minimum quantitative value for each spectrum
was calculated as the 5.0% of the highest peak. Protein
quantitative ratios were calculated as the median of all
peptide ratios. Due to limited quantity of mitochondria
samples, no technical replication was performed and so
we set the criteria of fold change >1.4 or <0.72 between
PBC mouse model and control for identifying differen-
tially expressed proteins, more stringent than that accepted
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were at >1.2 or <0.82. Data were further analyzed for
protein subcellular location and functional cluster using
Scaffold software based on NCBI online database and
UniProt database, respectively.
Western blotting
Individual or pooled mitochondria protein samples (5 ug)
were loaded for 12% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and gel
separated proteins were transferred to Polyvinylidene
fluoride (PVDF) membranes (Millipore, MA USA).
The membranes were blocked with 5% skimmed milk
dissolved in PBS with 0.1% Tween20 and then incu-
bated with 1:2,000 diluted primary antibodies generated
in rabbits (Beijing Protein Innovation Ltd., Co. Beijing,
China) at 37°C for 1 h. After washed with PBST for
10 min for three times, the membranes were incubated
with horseradish peroxidase (HRP) labeled sheep anti-
rabbit antibody (diluted 1:10,000) for 1.5 h at room
temperature. After rinsing the membrane with PBST, the
immune-recognition images from chemical-luminescent
signals using the ECL kit (Beijing Applygen Ltd.,Co.,
Beijing, China) were visualized by ImageQuant RT ECL
(GE Healthcare, Fairfield, CT, USA).
Results
Preparation of PBC mouse model
To study the proteome change in liver mitochondria at
early stage of PBC, we first prepared PBC mouse model
by consecutive injection of poly I:C to C57BL/6 mice.C1 4 weeks C2 8 w
M1 4 weeks M2 8 w
A B
D E
Figure 1 HE staining results of liver tissues from PBC mouse models a
images from control groups at 4, 8, and 12 weeks, respectively, showing no
the PBC mouse model group, showing that inflammatory cells infiltrated arWe collected liver samples at the end of four, eight, and
12 weeks, because during these time points the mice
would be in the early stage of PBC [11-13]. Histopatho-
logical analysis was performed to evaluate the progress of
the disease (Figure 1). As previously reported, with four
weeks of poly I:C injection, mice had already exhibited
PBC-like lesions at portal area, a characteristic of stage I
of PBC according to the guideline approved by AASLD
[5]. With eight and 12 weeks of injection, the lesions
were still limited in the portal area, but the inflammatory
cell infiltration was aggravated with increased numbers
of injections. Meanwhile, all mice in the control group
had none PBC-like lesions. We chose week 12 for com-
parative proteomics study by iTRAQ and the strategy is
shown in Figure 2A.
Mitochondria sample preparation
To identify the differentially expressed proteins in
mitochondria of PBC mouse models, we purified mito-
chondria from each mouse liver, extracted total pro-
teins and combined equal amount from the same group
at 12-week time point. The purity of mitochondria were
demonstrated by western blotting of total mitochondria
proteins and cytoplasm proteins using anti-ATP synthe-
sis subunit B (ATPase subunit B) and anti-Aldehyde re-
ductase (ALDR) antibodies (Figure 2B), target of
the former is specific to mitochondrial and the later is
to cytoplasm. The unique band recognized by anti-
ATPase subunit B antibody appeared in the purified
and crude mitochondrial samples but not in the cyto-
plasm fractions, while anti-ALDR antibody did noteeks C3 12 weeks
eeks M3 12 weeks
C
F
nd controls at various time points. A, B and C are the staining
abnormal alteration. While D, E and F are the staining images from























































































Figure 2 Procedure of quantitative iTRAQ proteomics. (A) Strategy for comparative proteomics study on the liver mitochondria between
mouse models and controls. (B) Evaluation of mitochondrial purity with organelle specific antibodies. (C) An example of the spectra, showing
peptide (ALALAQEILPQAPIAVR) which is one of the three unipeptides for Isoform 1 of Enoyl-CoA hydratase domain-containing protein 2 (ECHDC2).
(D) Distribution of peptides in each fraction according to their isoelectric points. Error bars show 95% confidence interval. (E) Quantities of peptide
spectra and proteins in each fraction.
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samples, indicating the purified mitochondria were in
good quality.
Comparative proteomics analysis by iTRAQ
To examine the difference in liver mitochondria prote-
ome between PBC mouse models and controls, we
conducted the analysis by iTRAQ. After trypsin diges-
tion of total mitochondrial proteins, peptides from the
model and control groups were labeled with 115 and
113, respectively. We then mixed the two samples,
separated the peptides based on isoelectric points by
IEF on a linear pH 3–10 strip, and extracted peptides
from 44 consecutive pieces along pH gradient. To
save the machine time, we first checked the peptide
quality and abundance in each fraction by MALDI-
TOF, and combined the adjacent fractions with
little peptides, resulting in a total of 18 fractions for
ESI-Q-TOF detection (Figure 2). Figure 2C shows arepresentative peptide spectrum of ESI-Q-TOF detec-
tion. Figure 2D shows the isoelectric point distribu-
tion of peptides identified in each of the 18 fractions,
clearly demonstrating the well separation of peptides
by IEF. Figure 2E shows the number of peptides and
proteins identified in each fraction. The majority of
peptides were distributed within the pI ranges of 4.1-
5.4, 5.92-6.49, and 7.71-8.26, the result was similar to
previously reported [23].
The MGF file merged from all the 18 fractions was
subjected to database searching by Mascot software. In
total, we identified 648 proteins. In order to make the
quantification more accurate, we performed protein
identification and quantification with Scaffold software
using following criteria: 1) Peptide identification was
more than 95% probability; 2) Protein identification was
greater than 99% probability; 3) At least two unique pep-
tides were identified for each protein. A total of 8978
spectra for 354 proteins satisfied the criteria. According to
Table 1 Down-regulated proteins in liver mitochondria of PBC mouse model
IPI_ID Uniprot name Protein name Ratio*
IPI00119940 CP17A_MOUSE Steroid 17-alpha-hydroxylase/17,20 lyase 0.54
IPI00225288 CC90B_MOUSE Isoform 1 of Coiled-coil domain-containing protein 90B 0.54
IPI00127223 B9EIY3_MOUSE UDP glucuronosyltransferase 2 family, polypeptide B36 0.57
IPI00890309 A2BIN1_MOUSE major urinary protein 10 0.57
IPI00850133 K0564_MOUSE Isoform 1 of Uncharacterized protein KIAA0564 homolog 0.66
IPI00119685 CP27A_MOUSE Sterol 26-hydroxylase, mitochondrial 0.71
IPI00127050 IPYR2_MOUSE Isoform 1 of Inorganic pyrophosphatase 2, mitochondrial 0.71
IPI00133240 UCRI_MOUSE Cytochrome b-c1 complex subunit Rieske, mitochondrial 0.71
IPI00316314 HACL1_MOUSE 2-hydroxyacyl-CoA lyase 1 0.71
*Ratio refers to protein ratio of PBC mouse model/control.
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(242/354) proteins are annotated mitochondrial proteins.
To analyze the quantitative data, we calculated ratios of
peptides with the median of corresponding spectra and ra-
tios of proteins with the median of corresponding peptides.
With a threshold at over 1.4 fold, 29 proteins were identi-
fied as differentially expressed proteins between mouse
models and controls at 12-week time point. Of these, nine
were down-regulated (Table 1, Additional file 1: Table S1)
and 20 were up-regulated in liver mitochondria of PBC
model mice (Table 2, Additional file 1: Table S2).Table 2 Up-regulated proteins in liver mitochondria of PBC m
IPI_ID Uniprot name Protein name
IPI00116222 3HIDH_MOUSE 3-hydroxyisobuty
IPI00120212 NDUA9_MOUSE NADH dehydrog
IPI00121105 HCDH_MOUSE Hydroxyacyl-coe
IPI00126050 PGCP_MOUSE Isoform 1 of Plas
IPI00309073 MTP_MOUSE Isoform 1 of Mic
IPI00319973 PGRC1_MOUSE Membrane-assoc
IPI00554961 FMO5_MOUSE dimethylaniline m
IPI00117914 ARGI1_MOUSE Arginase-1
IPI00225390 CX6B1_MOUSE Cytochrome c ox
IPI00118986 ATPO_MOUSE ATP synthase sub
IPI00123281 LRC59_MOUSE Leucine-rich repe
IPI00134870 ACOX2_MOUSE Peroxisomal acyl
IPI00307837 EF1A1_MOUSE Elongation facto
IPI00330094 CPT1A_MOUSE Carnitine O-palm
IPI00115598 DHB8_MOUSE Isoform Short of
IPI00221400 ADH1_MOUSE Alcohol dehydro
IPI00387379 DECR_MOUSE 2,4-dienoyl-CoA
IPI00469195 ECHD2_MOUSE Isoform 1 of Eno
IPI00757372 ISC2A_MOUSE Isochorismatase
IPI00169463 TBB2C_MOUSE Tubulin beta-2C
*Ratio refers to protein ratio of PBC mouse model/control.Differentially expressed proteins
In order to gain insight into the biological meaning of
the differentially expressed proteins in the liver mito-
chondria of PBC mouse models versus controls, Gene
Ontology (GO) analysis was performed and differential
proteins were categorized according to the cellular com-
ponent, biological process, and molecular function.
Based on analysis of the cellular component, 65.3% (17
of the 26 proteins with annotation information) of the
differentially expressed proteins were annotated mito-
chondrial proteins. In the molecular function analysis ofouse model
Ratio*
rate dehydrogenase, mitochondrial 1.41
enase [ubiquinone] 1 alpha subcomplex subunit 9, 1.41
nzyme A dehydrogenase, mitochondrial 1.41
ma glutamate carboxypeptidase 1.41
rosomal triglyceride transfer protein large subunit 1.41
iated progesterone receptor component 1 1.41
onooxygenase [N-oxide-forming] 5 1.41
1.47
idase subunit 6B1 1.51
unit O, mitochondrial 1.52
at-containing protein 59 1.52
-coenzyme A oxidase 2 1.52
r 1-alpha 1 1.52
itoyltransferase 1, liver isoform 1.52
Estradiol 17-beta-dehydrogenase 8 1.62
genase 1 1.74
reductase, mitochondrial 1.74
yl-CoA hydratase domain-containing protein 2, 1.75
domain-containing protein 2A, mitochondrial 1.87
chain 2.14
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http://www.biomedcentral.com/1471-230X/13/64GO analysis (Figure 3A), most differentially expressed
proteins were associated with function of binding (42%)
and catalytic activity (41%).
Classification analysis of the biological processes with
UniProt database and DAVID online tool (http://david.
abcc.ncifcrf.gov/) showed the differentially expressed
proteins are mainly involved in the processes of oxida-
tion reduction and lipid metabolism, including 11 and 8
proteins, respectively (Figure 3B-C). For the oxidation
reduction, three proteins were down-regulated and eight
were up-regulated in the liver mitochondria of PBC
mouse models. The down-regulated proteins were ster-
oid 17-alpha-hydroxylase/17,20 lyase (CYP17A1), sterol
26-hydroxylase (CYP27A), and cytochrome b-c1 com-
plex subunit Rieske (RISP). The up-regulated proteins
were 3-hydroxyisobutyrate dehydrogenase (HIBADH),
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex
subunit 9 (CI-39kD), hydroxyacyl-coenzyme A de-
hydrogenase (HCDH), dimethylaniline monooxygenase
[N-oxide-forming] 5 (FMO 5), peroxisomal acyl-coenzyme
A oxidase 2 (ACOX2), isoform short of estradiol 17-beta-
dehydrogenase 8 (17 beta-HSD 8), alcohol dehydrogenase
1 (ADH-A2), and 2,4-dienoyl-CoA reductase (DECR).
Among those proteins, two are associated with steroid hor-
mone biosynthesis; 17beta-HSD 8 was up-regulated, while
































Figure 3 GO classification of differentially expressed proteins in liver
analysis based on molecular functions. Gene function annotation showed t
reduction and (C) lipid metabolism.Additionally, CYP27A, involved in the metabolism of pri-
mary bile acid biosynthesis, was down-regulated in liver
mitochondria of PBC model.
Four of the eight proteins involved in the lipid meta-
bolic process, hydroxyacyl-coenzyme A dehydrogenase
(HCDH), carnitine O-palmitoyltransferase 1 (CPT I), 2,4-
dienoyl-CoA reductase (DECR), and isoform 1 of Enoyl-
CoA hydratase domain-containing protein 2 (ECHDC2),
specifically to fatty acid beta-oxidation system, the major
degradation pathway for fatty acid in humans. Interest-
ingly, all of the above four proteins were up-regulated
in liver mitochondria of PBC mouse models. In con-
trast, 2-hydroxyacyl-CoA lyase 1 (HACL1) in the fatty
acid alpha-oxidation setting was down-regulated.
Validation of differentially expressed proteins by western
blotting
To validate the differentially expressed proteins identi-
fied by iTRAQ technique, we used western blotting, a
semi-quantitative protein technique, to detect the ex-
pression of proteins in total liver mitochondria proteins
from PBC mouse model and controls. Eight proteins
were randomly selected from the differential expressed
proteins involved in oxidation reduction and/or lipid
metabolism. Peptides containing putative antigenic re-































mitochondria between PBC mouse model and controls. (A) GO
he differential proteins were mainly associated with (B) oxidation
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bodies (against ECHDC2, 17beta-HSD 8, and ADH-A2,
respectively) were in good quality, each recognized a
single band in total mitochondria protein at expected
molecular weight (data not shown). Validation by
western blotting was processed using the pooled and
individual mitochondrial samples in both PBC mouse
model and control groups at different time points
(Figure 4). For each protein, the signal intensities of
the pooled mitochondria samples from PBC mouse
model group at weeks 12 were significantly higher
than that from controls, which were consistent with
the result from iTRAQ (Figure 4A). For individual
mitochondria samples, there are large variations in
earlier weeks. Towards the later weeks, it was obvious
that the protein levels in PBC models were generally




Figure 4 Validation of three up-regulated mitochondria proteins b
17-beta-dehydrogenase 8 (17 beta-HSD 8), , Isoform 1 of Enoyl-CoA hydratase
(ADH-A2) were generated and used in western blotting with pooled mitochon
from individual mouse of both model and control groups at week 4 (B), 8 (C) a
of which had no significant difference between PBC model mice and controlsDiscussion
PBC is a liver specific chronic disease with unclear patho-
genesis, especially the molecular events at early stage. In
this study, we constructed the mouse model of early stage
of PBC using poly I:C administration to female C57BL/6,
performed the comparative proteomics study of liver
mitochondria between PBC model and control mice,
and identified several differentially expressed mito-
chondria proteins.
This PBC mouse model was first reported by Okada
et al. [11], who found administration of poly I:C induced
PBC like lesions, serologic AMA, and elevated alkaline
phosphatase activity, which are the three important diag-
nostic criteria for the disease. Studies have shown that
TLR3 pathway is critical in the pathogenesis of PBC
[24-26], and poly I:C, a synthetic double-stranded RNA,
can mimic the infection of retroviral RNA by interactingy western blotting. Antibodies against isoform short of estradiol
domain-containing protein 2 (ECHDC2), and alcohol dehydrogenase 1
dria protein at week 12, the same samples used in iTRAQ (A), and samples
nd 12 (D). ATPB was used as equal loading control marker, the expression
(R115/113 = 1.1).
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munity with series of cytokine production and activa-
tion of lymphocytes. This mouse model has been
repeatedly constructed by a number of laboratories for
uncovering the cellular and molecular events in patho-
genesis of PBC [12-14]. Similar to others, our model
also exhibited lymphocyte infiltration to the portal area
as early as 4 weeks after initiation of poly I:C injection,
and at the end of 12 weeks the model was still at stage I.
We employed iTRAQ method to analyze protein ex-
pression patterns in the liver mitochondria of PBC
model. Of all 354 proteins identified, 68.4% (242/354)
are annotated mitochondrial proteins, while others ei-
ther had no localization information or were annotated
within other compartments. The identification of pro-
teins annotated outside the target compartment was also
seen in other organelle proteomics research [27]. The
reason for that may be due to incomplete annotation,
strong interaction with the proteins located at outer
mitochondrial membrane, or contamination of trace
amount of other organelles.
Our comparative proteomics research on the liver
mitochondria identified nine down-regulated and 20 up-
regulated proteins in PBC mouse model. The differen-
tially expressed proteins are mainly involved in the
process of oxidation reduction and lipid metabolism.
Among the 11 proteins that are associated with oxidation
reduction, one reductase, two oxidases, and five dehydro-
genases were significantly up-regulated, which might sat-
isfy a higher demand of energy for the inflammatory
response [28] seen early on in the PBC model as the infil-
tration of the inflammatory cells around bile duct
(Figure 1). Additionally, increased alcohol dehydrogenase
had been shown to associate with inflammatory response
and the Reactive Oxygen Species (ROS) in the develop-
ment of alcoholic liver disease [29]. In our study, alcohol
dehydrogenase is confirmed up-regulated (Figure 4), and
it might function in inflammatory response in the devel-
opment of PBC as well. On the other hand, in the lipid
metabolism, all the four proteins associated with beta-
oxidation, the classic pathway for the degradation of fatty
acid, were up-regulated. While in patients with alcohol-
and obesity-induced fatty liver diseases, impaired mito-
chondrial fatty acid beta-oxidation plays a key role in
liver steatosis, fibrosis, and eventually cirrhosis [30,31].
So, the phenomenon that four proteins involved in beta
oxidation were up-regulated suggests that there might be
a protective mechanism to keep hepatocytes healthy in
early stage PBC, and it might be the stress response to
poly I:C and inflammation.
Among the down-regulated proteins, steroid 17-alpha-
hydroxylase/17,20 lyase, also known as cytochrome
P450 17A1 (CYP17A1), is a single enzyme with both
17α-hydroxylase and 17,20-lyase activities. It is thekey rate-limiting enzyme involved in the initial steps
of steroidogenesis [32]. CYP17A1 is related with liver
toxicities caused by its product, 17-αhydroxysteroids
[33]. Down-regulation of CYP17A1 in our PBC mouse
model might be the stress response at early stage of
PBC to decrease the toxicity to the cell. In addition,
sterol 26-hydroxylase (CYP27A) is an important en-
zyme, not only in the formation of bile acids from chol-
esterol intermediates in the liver but also in the
removal of cholesterol by side chain hydroxylation in
extrahepatic tissues [34]. Experiments with bile duct-
ligated hamsters showed that bile acid biosynthetic
pathway via mitochondrial CYP27A was preferentially
inhibited [35]. PBC is a cholestasis liver disease. Mouse
model used in this study is in early stages, down-
regulated expression of CYP27A might be a predictor
for the destruction of bile duct.
Finally, it should point out that our findings are mainly
based on iTRAQ analysis. Although the successful valid-
ation of 3 differential proteins by Western blotting
greatly increases our confidence in iTRAQ results, the
certainty of the other 26 differential proteins still remain
to be validated once specific antibododies are available.
Conclusions
In conclusion, through the comparative proteomics
study on the liver mitochondria of PBC mouse model,
we identified 29 differentially expressed proteins. Most
are involved in lipid metabolism and oxidation reduc-
tion, and some are involved in the biosynthesis of steroid
hormone and primary bile acid. All four differentially
expressed proteins involved in fatty acid beta oxidation
and most proteins associated with oxidation reductive
were up-regulated. Our results provide some insights for
the mechanism of pathogenesis in early stage of PBC.
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